Cancer Immunotherapy Market Size to Reach USD 339.6 Billion by 2032 | CAGR: 14.5% | DataHorizzon Research

Fort Collins, Colorado, Sept. 14, 2023 (GLOBE NEWSWIRE) -- DataHorizzon Research Published a report titled, "Cancer Immunotherapy Market Size, Growth, Share, Statistics Report, By Type (Monoclonal antibodies, Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Others), By End-user, By Region, And Segment Forecasts, 2023-2032." 

According to DataHorizzon Research, The cancer immunotherapy market size was valued at USD 88.1 Billion in 2022 and is expected to reach USD 339.6 Billion by 2032 to exhibit a CAGR of 14.5%. Cancer immunotherapy is a treatment that boosts body's natural ability to fight cancer. Compared to older techniques, this therapy offers longer-lasting protection, with fewer side effects and effectiveness against a broader range of cancers. This treatment is used for different cancers, including melanoma, prostate, breast, colorectal, lung, head & neck, and many others. 

Immunotherapy involves using the immune system to target cancer cells and activate a response that can destroy them. The cancer immunotherapy market is expected to grow due to various factors, including increased healthcare spending, higher cancer rates, improved access to medical insurance, and advancements in cancer treatment technology.

Request Sample Report: https://datahorizzonresearch.com/request-sample-pdf/cancer-immunotherapy-market-2350 

Report Snapshot:

Segmentation Overview

The market for cancer immunotherapy has seen a significant increase in monoclonal antibody usage, which currently dominates the market. These antibodies possess unique properties that enable them to modulate the immune system by activating or inhibiting targeted molecules. Within this market, the segment for lung cancer holds the highest dominance due to the rising incidence of lung malignancies, increased adoption of immunotherapy, expanded awareness programs, and a robust pipeline of investigational candidates.

North America dominates the healthcare market due to increased spending, focus on maintaining a top healthcare system, and rising cancer rates globally. This increase in cancer prevalence is due to the region's high cancer rates and the growing use of cancer immunotherapy.

Buy This Research Report: https://datahorizzonresearch.com/checkout-page/cancer-immunotherapy-market-2350 

Key Developments in the Cancer Immunotherapy Market:

• The National Urban League and Takeda have launched a health equity initiative to address barriers that hinder access to healthcare for marginalized populations in the US.

• GlaxoSmithKline Pharmaceuticals Ltd has launched Shingrix in India, a vaccine that helps prevent shingles and post-herpetic neuralgia for adults aged 50 and above. 

Cancer Immunotherapy Market Report Highlights:

• The cancer immunotherapy market size is expected to reach at a CAGR of 14.5% by 2032. Immunotherapy is a treatment for diseases such as cancer that uses the body's immune system to fight the disease. It can be done by either boosting the immune system's effectiveness or introducing artificial immune system proteins into the body. This therapy helps to enhance the body's natural defences against cancer.

• Monoclonal antibodies dominate the cancer immunotherapy market, with lung cancer being the leading segment due to rising incidence, adoption of immunotherapy, awareness programs, and investigational candidates.

• Major players in the market are Pfizer Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Seagen Inc., Gilead Sciences Inc., Immunocore, Ltd., Amgen, Inc., Eli Lily And Company, Bayer AG, Janssen Biotech, Inc., Spectrum Pharmaceuticals Inc., Sanofi, Takeda Pharmaceuticals, Celgene Corp, Immunomedics, Medivation, Advaxis, GlaxoSmithKline Pharmaceuticals Ltd., Viralytics, Astellas Pharma Inc., OSE Immunotherapeutics, Sun Pharmaceutical Industries Ltd, Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Bausch Health, and LUPIN.

Looking Exclusively For Region/Country Specific Report? https://datahorizzonresearch.com/ask-for-customization/cancer-immunotherapy-market-2350

OR

Ask For Discount https://datahorizzonresearch.com/ask-for-discount/cancer-immunotherapy-market-2350 

Cancer Immunotherapy Market Report Segmentation:

Cancer Immunotherapy Market, By Type (2023-2032)

• Monoclonal Antibodies
• Cancer Vaccines
• Checkpoint Inhibitors
• Immunomodulators

Cancer Immunotherapy Market, By Application (2023-2032)

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head & Neck Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

Cancer Immunotherapy Market, By End-user (2023-2032)

• Hospitals
• Cancer Research Center
• Others

Cancer Immunotherapy Market, By Region (2023-2032)

• North America

• • U.S.
  • Canada

• Europe

• • U.K.
  • Germany
  • France
  • Rest of Europe 

• Asia Pacific

• • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific

• Latin America

• • Brazil
  • Mexico
  • Rest of Latin America

• The Middle East & Africa

• • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa 

About DataHorizzon Research:

DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR’s comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.

Contact:

Mail: sales@datahorizzonresearch.com

Ph: +1-970-672-0390

Website: https://datahorizzonresearch.com/

Follow Us: LinkedIn

Recent Publications

Infertility Treatment Market 2023 to 2032
Dexamethasone Market 2023 to 2032
Microfluidics Market 2023 to 2032
Biosimilars Market 2023 to 2032
Advanced Wound Care Market 2023 to 2032